Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.03 is 23% below its 4-year average of 0.03, around the middle of its 4-year range (-0.83–0.57).
As of the fiscal period ended Tuesday, June 30, 2026. 20.00% above its 12-month average of 0.02.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.03.
DEBT TO EQUITY RATIO
0.03
DEBT TO EQUITY RATIO AVG TTM
0.02
DEBT TO EQUITY RATIO AVG 3Y
0.02
DEBT TO EQUITY RATIO AVG 5Y
N/A
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+20.00%
CURRENT VS 3Y AVG
+18.29%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.13
median of 586 covered companies
CURRENT VS SECTOR MEDIAN
-80.09%
vs the sector median at left
Mangoceuticals, Inc.
Market Cap
$7.17M
Debt to Equity Ratio
0.03
TTM Avg
0.02
3Y Avg
0.02
5Y Avg
N/A
Market Cap
$7.07M
Debt to Equity Ratio
0.14
TTM Avg
0.05
3Y Avg
0.03
5Y Avg
0.02
Market Cap
$7.31M
Debt to Equity Ratio
0.00
TTM Avg
0.03
3Y Avg
0.05
5Y Avg
0.05
Market Cap
$7.02M
Debt to Equity Ratio
N/A
TTM Avg
0.03
3Y Avg
0.02
5Y Avg
0.01
Market Cap
$7.35M
Debt to Equity Ratio
0.06
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.01
Market Cap
$6.60M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Mangoceuticals, Inc. (MGRX) | $7.17M | 0.03 | 0.02 | 0.02 | N/A |
| Co-Diagnostics, Inc. (CODX)vs › | $7.07M | 0.14 | 0.05 | 0.03 | 0.02 |
| InMed Pharmaceuticals Inc. (INM)vs › | $7.31M | 0.00 | 0.03 | 0.05 | 0.05 |
| NeuroSense Therapeutics Ltd. (NRSN)vs › | $7.02M | N/A | 0.03 | 0.02 | 0.01 |
| KALA BIO, Inc. (KALA)vs › | $7.35M | 0.00 | 1.31 | 2.43 | 2.58 |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.35M | 0.06 | 0.01 | 0.01 | 0.01 |
| Longeveron Inc. (LGVN)vs › | $7.47M | 0.06 | 0.11 | 0.16 | 0.47 |
| Aclarion, Inc. (ACON)vs › | $6.73M | 0.00 | 0.00 | 0.00 | 0.00 |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.60M | 0.00 | 0.00 | 0.00 | 0.00 |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.49M | 1.71 | 0.66 | 0.41 | 0.34 |
Debt/Equity
0.03
Current Ratio
0.18
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.03 |
| 2026-03-31 | 0.02 |
| 2025-12-31 | 0.02 |
| 2025-09-30 | 0.01 |
| 2025-06-30 | 0.03 |
| 2025-03-31 | 0.00 |
| 2024-12-31 | 0.02 |
| 2024-09-30 | 0.02 |
| 2024-06-30 | 0.02 |
| 2024-03-31 | -0.21 |
| 2023-12-31 | 0.17 |
| 2023-09-30 | 0.11 |
| 2023-06-30 | 0.05 |
| 2023-03-31 | 0.07 |
| 2022-12-31 | 0.57 |
| 2022-09-30 | 0.11 |
| 2022-06-30 | -0.83 |
| 2022-03-31 | 0.00 |
| 2021-12-31 | 0.00 |
